[1] Bailey AL, Diamond MS. Hepatopathology of flaviviruses.J Hepatol,2022,77(6):1711-1713.
[2] Rathore APS, St John AL. Cross-Reactive Immunity Among Flaviviruses.Front Immunol, 2020,11:334.
[3] Lien CE, Chou YJ, Shen YJ, et al. A population-based cohort study on chronic comorbidity risk factors for adverse dengue outcomes.Am J Trop Med Hyg, 2021,105(6):1544-1551.
[4] Kye Mon K, Nontprasert A, Kittitrakul C, et al. Incidence and Clinical Outcome of Acute Liver Failure Caused by Dengue in a Hospital for Tropical Diseases, Thailand.Am J Trop Med Hyg, 2016,95(6):1338-1344.
[5] Seneviratne SL, Malavige GN, de Silva HJ. Pathogenesis of liver involvement during dengue viral infections.Trans R Soc Trop Med Hyg, 2006,100(7):608-614.
[6] Douam F, Ploss A. Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.Trends Microbiol, 2018,26(11):913-928.
[7] Tuboi SH, Costa ZG, da Costa Vasconcelos PF, et al. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans R Soc Trop Med Hyg, 2007,101(2):169-175.
[8] Bailey AL, Kang LI, De Assis Barros D'Elia Zanella LGF, et al. Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury. Proc Natl Acad Sci USA,2020,117(51):32648-32656.
[9] Douam F, Ploss A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol, 2018,26:913-928.
[10] Kallas EG, D'Elia Zanella LGFAB, Moreira CHV, et al. Predictors of mortality in patients with yellow fever: an observational cohort study.Lancet Infect Dis, 2019,19(7):750-758.
[11] Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever.Adv Virus Res, 2003,60:343-395.
[12] Vieira V, Pacheco L, Demetrio L, et al. Liver Transplantation for Acute Liver Failure due to Yellow Fever: A Case Report.Transplant Proc,2019,51(5):1625-1628.
[13] Song ATW, Abdala E, de Martino RB, et al. Liver Transplantation for Fulminant Hepatitis Attributed to Yellow Fever.Hepatology,2019,69(3):1349-1352.
[14] Monath TP. Treatment of yellow fever. Antiviral Res,2008,78(1):116-124.
[15] de Freitas CS, Higa LM, Sacramento CQ, et al. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.PLoS Negl Trop Dis,2019,13(1): e0007072.
[16] Mendes ÉA, Pilger DRB, Santos Nastri ACS, et al. Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure.Ann Hepatol,2019,18(6):816-824.
[17] Vellozzi C, Mitchell T, Miller E, et al. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.Am J Trop Med Hyg,2006,75(2):333-336.
[18] Sejvar JJ. Clinical manifestations and outcomes of West Nile virus infection.Viruses, 2014,6(2):606-623.
[19] Halani S, Tombindo PE, O'Reilly R, et al. Clinical manifestations and health outcomes associated with Zika virus infections in adults: A systematic review.PLoS Negl Trop Dis, 2021,15(7): e0009516.
[20] Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines.Hum Vaccin Immunother,2014,10(2):263-279.
[21] Taba P, Schmutzhard E, Forsberg P, et al. EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis.Eur J Neurol, 2017,24(10):1214-e61.
[22] Suss J. Tick-borne encephalitis in Europe and beyond--the epidemiological situation as of 2007.Euro Surveill,2008,13(26):18916.
[23] Donoso Mantke O, Escadafal C, Niedrig M, et al. Tick-borne encephalitis in Europe, 2007 to 2009.Euro Surveill,2011,16(39):19976.
[24] Bogovic Petra, Strle Franc. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J Clin Cases, 2015, 3: 430-41.
[25] Ruzek D, Avšič Županc T, Borde J, et al. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. Antiviral Res, 2019, 164: 23-51. |
